• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FV Leiden基因多态性患者长期口服避孕药未发生血栓形成:37例患者(2例纯合子和35例杂合子)的研究

Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous).

作者信息

Girolami A, Tormene D, Gavasso S, Bertolo C, Girolami B

机构信息

University of Padua Medical School, Department of Medical and Surgical Sciences, Second Chair of Medicine, Padua, Italy.

出版信息

J Thromb Thrombolysis. 2004 Apr;17(2):145-9. doi: 10.1023/B:THRO.0000037671.98201.15.

DOI:10.1023/B:THRO.0000037671.98201.15
PMID:15306751
Abstract

It is commonly accepted that women on oral contraceptive therapy have about a four fold increased incidence of venous thrombosis in comparison to non users. Women with FV Leiden polymorphism have an even higher incidence. The purpose of the paper is to show that women with FV Leiden polymorphism may sometimes remain asymptomatic in spite of long-term use of oral contraceptives. We have studied and followed 37 women with this polymorphism (35 heterozygotes and 2 homozygotes) who remained asymptomatic even after a long use, occasionally up to 10-12 years of oral contraception. Furthermore, these women remained asymptomatic in spite of the fact that the majority of them took preparations containing third generation progestins (gestodene or desogestrel). These progestins are considered to be more thrombogenic as compared to older ones. Finally, several of these women became pregnant before, during interruptions or after the contraceptive therapy and remained also asymptomatic but for one patient with varicose veins who developed superficial phlebitis during one pregnancy. These data indicate that FV Leiden polymorphism, as far as oral contraceptive therapy is concerned, is not a very strong prothrombotic condition and probably does not represent an absolute contraindication to its use. Unfortunately so far there is no sure way to distinguish the women with this polymorphism who will develop venous thrombosis from those who will remain asymptomatic during oral contraceptive therapy.

摘要

人们普遍认为,与未服用口服避孕药的女性相比,服用口服避孕药的女性静脉血栓形成的发生率增加了约四倍。携带FV莱顿多态性的女性发生率更高。本文的目的是表明,尽管长期使用口服避孕药,但携带FV莱顿多态性的女性有时可能仍无症状。我们研究并跟踪了37名具有这种多态性的女性(35名杂合子和2名纯合子),她们即使长期使用口服避孕药(偶尔长达10至12年)也仍无症状。此外,尽管这些女性中的大多数服用了含有第三代孕激素(孕二烯酮或去氧孕烯)的制剂,但她们仍无症状。与 older ones相比,这些孕激素被认为具有更强的血栓形成作用。最后,这些女性中有几位在避孕治疗前、期间中断或之后怀孕,并且除了一名患有静脉曲张的患者在一次怀孕期间发生了浅静脉炎外,其余也都无症状。这些数据表明,就口服避孕药治疗而言,FV莱顿多态性并非很强的促血栓形成状况,可能也不代表使用它的绝对禁忌症。不幸的是,到目前为止,尚无确定的方法来区分在口服避孕药治疗期间会发生静脉血栓形成的携带这种多态性的女性和那些仍无症状的女性。

相似文献

1
Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous).FV Leiden基因多态性患者长期口服避孕药未发生血栓形成:37例患者(2例纯合子和35例杂合子)的研究
J Thromb Thrombolysis. 2004 Apr;17(2):145-9. doi: 10.1023/B:THRO.0000037671.98201.15.
2
Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?对凝血因子V莱顿突变进行选择性筛查:在开具口服避孕药之前这样做是否可取?
Thromb Haemost. 1997 Dec;78(6):1480-3.
3
Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.口服避孕药会增加纯合子型凝血因子V莱顿突变女性在年轻时出现静脉血栓临床表现的风险。
Br J Haematol. 1996 May;93(2):487-90. doi: 10.1046/j.1365-2141.1996.5712013.x.
4
Probability of recurrence of thrombosis in patients with and without factor V Leiden.有和没有凝血因子V莱顿突变的患者血栓形成复发的概率。
Thromb Haemost. 1996 Feb;75(2):229-32.
5
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.携带凝血因子V莱顿突变的口服避孕药使用者发生静脉血栓形成的风险增加。
Lancet. 1994 Nov 26;344(8935):1453-7. doi: 10.1016/s0140-6736(94)90286-0.
6
[Factor V leiden and venous thromboembolism in a woman taking second generation oral contraceptives: a case report].[一名服用第二代口服避孕药的女性中的因子V莱顿突变与静脉血栓栓塞:病例报告]
Ginekol Pol. 1999 Feb;70(2):93-7.
7
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.第二代和第三代口服避孕药及其各自的孕激素在存在或不存在凝血因子V Leiden突变的情况下对凝血系统的影响。
Thromb Haemost. 2002 Feb;87(2):199-205.
8
Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group.口服避孕药使用者及遗传性血栓形成倾向携带者发生脑静脉窦血栓形成风险的病例对照研究。脑静脉窦血栓形成研究组。
BMJ. 1998 Feb 21;316(7131):589-92. doi: 10.1136/bmj.316.7131.589.
9
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use.年轻女性的静脉血栓栓塞;血栓形成倾向突变和口服避孕药使用的作用。
Eur Heart J. 2002 Jun;23(12):984-90. doi: 10.1053/euhj.2001.3082.
10
Oral contraceptives and the risk of myocardial infarction.口服避孕药与心肌梗死风险
N Engl J Med. 2001 Dec 20;345(25):1787-93. doi: 10.1056/NEJMoa003216.

引用本文的文献

1
Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?
J Thromb Thrombolysis. 2008 Oct;26(2):163-4. doi: 10.1007/s11239-007-0180-z. Epub 2007 Dec 23.

本文引用的文献

1
Changes in prescription patterns of oral contraceptives in a northern Italian province: relation with venous thromboembolism.意大利北部某省口服避孕药处方模式的变化:与静脉血栓栓塞的关系。
Clin Appl Thromb Hemost. 2003 Apr;9(2):125-30. doi: 10.1177/107602960300900206.
2
Proposal of a flow chart for thrombosis-free oral contraceptive therapy.无血栓形成口服避孕药治疗流程图的提议。
Clin Appl Thromb Hemost. 2003 Jan;9(1):33-7. doi: 10.1177/107602960300900104.
3
Long-term use of oral contraceptive therapy in women with the prothrombin 20210 G-A polymorphism without thrombotic complications: a study of 13 women (12 heterozygotes and 1 homozygote).
凝血酶原20210 G-A基因多态性且无血栓形成并发症的女性长期口服避孕药治疗:13名女性(12名杂合子和1名纯合子)的研究
Thromb Res. 2001 May 1;102(3):205-10. doi: 10.1016/s0049-3848(01)00239-0.
4
Oral contraceptives and the risk of venous thrombosis.口服避孕药与静脉血栓形成风险
N Engl J Med. 2001 May 17;344(20):1527-35. doi: 10.1056/NEJM200105173442007.
5
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.
Blood. 2000 Nov 15;96(10):3329-33.
6
Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism.未选择的静脉血栓栓塞患者中因子V莱顿突变和凝血酶原G20210A突变的患病率。
Br J Haematol. 2000 Jul;110(1):125-9. doi: 10.1046/j.1365-2141.2000.02039.x.
7
Biological coagulation findings in third-generation oral contraceptives.第三代口服避孕药的生物凝血研究结果。
Hum Reprod Update. 1999 Nov-Dec;5(6):672-80. doi: 10.1093/humupd/5.6.672.
8
Two additional homozygous patients for the 20210 prothrombin polymorphism with no venous thrombosis.另外两名20210凝血酶原多态性纯合子患者,无静脉血栓形成。
Thromb Res. 1999 Dec 1;96(5):415-7. doi: 10.1016/s0049-3848(99)00131-0.
9
Thrombophilia as a multigenic disease.血栓形成倾向作为一种多基因疾病。
Haematologica. 1999 Jan;84(1):59-70.
10
Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation.凝血因子V莱顿突变先证者无症状亲属中静脉血栓栓塞发生率较低。
Ann Intern Med. 1999 Mar 16;130(6):538. doi: 10.7326/0003-4819-130-6-199903160-00012.